Diagnosis and treatment of head and neck sarcoma

doi:10.19438/j.cjoms.2024.04.015

Abstract

Abstract: Sarcoma is a low-occurrence malignant tumor,head and neck sarcoma has a lower incidence rate. Due to the low probability of sarcoma and the lack of obvious early clinical symptoms, it is difficult to diagnose before treatment. Diagnosis needs to integrate clinical symptoms and imaging, pathological findings, and tumor markers, etc. At present, the key technical point for treatment of sarcoma is still wide margin surgery. Chemotherapy, radiotherapy, targeted and immunotherapy can enhance the treatment effect or improve the prognosis. Advances in research on new biomarkers and photodynamic therapy can provide more ways for the diagnosis and treatment of sarcomas in the future. The purpose of this article is to briefly describe the current mainstream diagnosis and treatment methods for head and neck sarcomas and prospects for future diagnosis and treatment.

Key words: Head and neck sarcoma, Diagnosis, Biomarkers, Surgical treatment, Adjuvant radiotherapy and chemotherapy

CLC Number:

R739.8

GUO Yi-fei, ZHANG Yong-hong, REN Zhen-hu. Diagnosis and treatment of head and neck sarcoma[J]. China Journal of Oral and Maxillofacial Surgery, 2024, 22(4): 404-408.

References

[1] Kobayashi K, Hanai N, Yoshimoto S, et al.Current topics and management of head and neck sarcomas[J]. Jpn J Clin Oncol, 2023, 53(9):743-756.
[2] Grünewald TG, Alonso M, Avnet S, et al.Sarcoma treatment in the era of molecular medicine[J]. EMBO Mol Med, 2020, 12(11): e11131.
[3] Peng KA, Grogan T, Wang MB.Head and neck sarcomas: analysis of the SEER Database[J]. Otolaryngol Head Neck Surg, 2014, 151(4): 627-633.
[4] Mirabello L, Troisi RJ, Savage SA.Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program[J]. Cancer, 2009, 115(7): 1531-1543.
[5] Chen YM, Gokavarapu S, Shen QC, et al.Chemotherapy in head and neck osteosarcoma: adjuvant chemotherapy improves overall survival[J]. Oral Oncol, 2017, 73(1): 124-131.
[6] Atarbashi-Moghadam S, Emami Razavi AN, Salehi Zalani S.Prevalence of head and neck sarcoma in a major cancer center in Iran-a 10-year study[J]. Iran J Otorhinolaryngol, 2019, 31(103): 97-102.
[7] Subhawong TK, Wilky BA.Value added: functional MR imaging in management of bone and soft tissue sarcomas[J]. Curr Opin Oncol, 2015, 27(4): 323-231.
[8] Crozat A, Aman P, Mandahl N, et al.Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma[J]. Nature, 1993, 363(6430): 640-644.
[9] Hahm KB, Cho K, Lee C, et al.Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein[J].Nat Genet, 1999, 23(2): 222-227.
[10] Roeb W, Boyer A, Cavenee WK, et al.PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation ofEGR1[J]. Proc Natl Acad Sci USA, 2007, 104(46): 18085-18090.
[11] Wunder JS, Eppert K, Burrow SR, et al.Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas[J]. Oncogene, 1999,18(3): 783-788.
[12] Martin S, Clark SE, Gerrand C, et al.Patients' experiences of a sarcoma diagnosis: a process mapping exercise of diagnostic pathways[J].Cancers (Basel), 2023, 15(15): 3946.
[13] Sarcoma UK. Impact of sarcoma: national sarcoma survey2020[R/OL]. https://sarcoma.org.uk/wp-content/uploads/2022/05/impact_of_sarcoma_2020_national_sarcoma_survey_-_technical_report_-_accessible.pdf.
[14] 戴振霖, 艾哈迈德·阿德热罕穆, 陈一铭, 等. 新辅助化疗治疗头颈部骨肉瘤单中心临床效果回顾[J]. 中国口腔颌面外科杂志, 2021, 19(2): 132-137.
Dai ZL, Aihamaide A, Chen YM, et al.Clinical efficacy of neoadjuvant chemotherapy in the treatment of head and neck osteosarcoma[J]. China Journal of Oral and Maxillofacial Surgery, 2019, 19(2): 132-137.
[15] Patrikidou A, Domont J, Cioffi A, et al.Treating soft tissue sarcomas with adjuvant chemotherapy[J]. Curr Treat Options Oncol, 2011, 12(1): 21-31.
[16] National Comprehensive Cancer Network. NCCN guideline for bone cancer.Version 1[Z/OL]. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1418.
[17] 张陈平. 口腔癌的间室外科[C]//2011国际暨全国第十一届头颈肿瘤学术大会会议论文集. 杭州: 中国抗癌协会, 2011.
Zhang CP.The interfacial department of oral cancer[C]//Proceedings of the 11th International and National Academic Congress on Head and Neck Oncology in 2011. Hangzhou: Chinese Anti-Cancer Association, 2011.
[18] 贾东东, 夏李明, 金谷, 等. 软组织肉瘤外科治疗进展[J].肿瘤学杂志, 2018, 24(8): 823-827.
Jia DD, Xia LM, Jin G, et al.Surgical treatment of soft tissue sarcoma[J]. Journal of Oncology, 2018, 24(8): 823-827.
[19] Sakamoto A, Iwamoto Y.Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy[J]. Rev Recent Clin Trials, 2008,3(3): 228-231.
[20] Judson I, Verweij J, Gelderblom H, et al.Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlledphase 3 trial[J]. Lancet Oncol,2014, 15(4): 415-423.
[21] 邱蔚六, 郑家伟. 应重视口腔颌面部恶性肿瘤的综合序列治疗[J]. 中国口腔颌面外科杂志, 2005, 3(3):179-182.
Qiu WL, Zheng JW.Comprehensive sequential therapy for oral and maxillofacial malignancy[J]. China Journal of Oral and Maxillofacial Surgery, 2005, 3(3): 179-182.
[22] Thariat J, Schouman T, Brouchet A, et al.Osteosarcomas of the mandible: multidisciplinary manage-ment of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE[J]. Ann Oncol, 2013, 24(3):824-831.
[23] 李晓, 季彤. 颌面头颈部骨肉瘤化学治疗的研究进展[J].国际口腔医学杂志, 2017, 44(1): 83-86.
Li X, Ji T.Research progress of chemotherapy for maxillofacial head and neck osteosarcoma[J]. International Journal of Stomatology, 2017, 44(1): 83-86.
[24] Yoon SS, Chen YL, Kirsch DC, et al.Proton-beam, intensity-modulated, and/or intraoperative electron radiation therapy combined with aggressive anterior surgical resection for retroperitoneal sarcomas[J]. Ann Surg Oncol, 2010, 17(6): 1515-1529.
[25] Dangoor A, Seddon B, Gerrand C, et al.UK guidelines for the management of soft tissue sarcomas[J]. Clin Sarcoma Res, 2016, 6(1):20-46.
[26] Smithey BE, Pappo AS, Hill DA.C-kit expression in pediatric solid tumors: a comparative immunohistochemical study[J]. Am J Surg Pathol, 2002, 26(4): 486-492.
[27] Wilhelm SM, Carter C, Tang L, et al.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J]. Cancer Res, 2004, 64(19): 7099-7109.
[28] 崔抗, 赵瑞华, 冯涵. 软组织肉瘤靶向治疗药物的研究进展[J].中国临床新医学, 2019, 12(4): 366-371.
Cui K, Zhao RH, Feng H.Research progress of targeted therapeutic drugs for soft tissue sarcoma[J]. Chinese Journal of Clinical Oncology, 2019, 12(4): 366-371.
[29] 季彤. 头颈部骨肉瘤规范化诊断与治疗[C]//2019第一届全国口腔颌面-头颈肿瘤学术大会—聚合引领、协同发展论文汇编.上海: 中华口腔医学会, 2019.
Ji T.Standardized diagnosis and treatment of head and neck osteosarcoma[C]//2019 the first national oral and maxillofacial-head and neck tumor academic conference--aggregation leading and collaborative development. Shanghai: Chinese Stomatological Association, 2019.
[30] Matsubara T, Kusuzaki K, Matsumine A, et al.Acridine orange used for photodynamic therapy accumulates in malignant musculoskeletal tumors depending on pH gradient[J]. Anticancer Res, 2006, 26(1A): 187-193.
[31] Matsubara T, Kusuzaki K, Matsumine A, et al.Can a less radical surgery using photodynamic therapy with acridine orange be equal to a wide-margin resection?[J]. Clin Orthop Relat Res, 2013, 471(3): 792-802.
[32] Kusuzaki K, Takai T, Yoshimura H, et al.Clinical trial of radiotherapy after intravenous injection of acridine orange for patients with cancer[J].Anticancer Res, 2018, 38(1): 481-489.
[33] Martano M, Morello E, Avnet S, et al.Photodynamic surgery for feline injection-site sarcoma[J].BioMed Res Int, 2019: 8275935.
[34] 陈一铭, Ahmed, 季彤, 等. 101例头颈部横纹肌肉瘤临床、病理及预后分析[J].中国口腔颌面外科杂志, 2022, 20(2): 146-150.
Chen YM, Ahmed, Ji T, et al.Clinical, pathological and prognostic analysis of 101 cases of rhabdomyosarcoma of head and neck[J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(2): 146-150.